🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What would you do with 1000+ spatial transcriptomics samples with corresponding H&E-stained whole-slide images? Meet HEST-1k, a collection of 1,108 ST samples assembled from 131 public and internal cohorts encompassing 25 organs, 2 species. HEST-1k includes over 1.5 million

Academic and industry folks, I’ll attend AACR in Chicago this year. Would love to catch up if you’re around and see what new things have emerged in #prostate cancer #RWE #RLT

CAR-T therapy in solid tumors dlvr.it/TKHWmC

Online Now: Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation dlvr.it/TKJf0T

Super exciting to see our first publication, led by talented postdoc Dr. Zhao in 2012, has led to something that will soon benefit patients! EZH2 and AR cooperate to repress tumor suppressors, which can be rescued by their inhibitor combo to suppress prostate cancer, per Pfizer Inc.!

🔬Not just mutations. 🧬Not just methylation. The new frontier in early cancer detection? The cfDNA fragmentome—size, shape, structure, and silence. nature International Society of Liquid Biopsy OncoAlert doi.org/10.1038/s41568…

📘mCRPC guideline update ASCO Journal of Clinical Oncology 👉doi.org/10.1200/JCO-25… OncoAlert #cancer #oncology #MedX #ASCO25

Spatial omics data starting to show some good clinical utility: "Spatial immune scoring system predicts hepatocellular carcinoma recurrence" nature.com/articles/s4158… likely the tip of the molecular iceberg nature

Spatial transcriptomic profiling to characterize the nature of peripheral- versus transition-zone #ProstateCancer. #AuthorCommentary Parth Patel, MD and Simpa Salami Michigan Urology discuss the biological and molecular distinctions between #PCa originating in the peripheral zone vs

Important publicly available resource from Tirosh Lab Weizmann Institute in Nature Cancer The Curated Cancer Cell Atlas provides a comprehensive characterization of tumors at single-cell resolution nature.com/articles/s4301… 124 single cell datasets across 40 cancers, >2800 samples.

Yale and Google trained a 27B parameter model, C2S-Scale, to unify single-cell transcriptomics and biological language for deep reasoning across genes and cells. It outperforms prior models in interpretation, QA, and perturbation prediction using reinforcement learning

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

Cell-type deconvolution methods for spatial transcriptomics | Nature Reviews Genetics nature.com/articles/s4157…

KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy: Cancer Cell cell.com/cancer-cell/ab…

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: biomarker study of four phase 3 controlled trials thelancet.com/journals/landi…

High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer | Nature Genetics nature.com/articles/s4158…

Tour de force pancreas cancer study in @nature by Anirban Maitra (Anirban Maitra) MD Anderson Cancer Center, revealing profound transcriptomic heterogeneity & TME dynamics in metastases. Interesting CAF dynamics associated with cell state changes -- super cool. doi.org/10.1038/s41586…

1/ You think clinical trial genomics is simple: compare pre‑ vs post‑treatment RNA‑seq. But even getting clean metadata? That’s a war.

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer Nature Communications rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab Dana-Farber Lank Center for Genitourinary Oncology PCF Science

For an extensive overview of current and emerging #neoadjuvant #IO data across tumor types incl NSCLC, TNBC, CRC, esophagogastric + bladder cancers, melanoma and many more: So much we can learn from each other: immerse yourself! #ESMOGI25 Nature Cancer doi.org/10.1038/s43018…